News

November 14, 2017

Potential heart attack or just chest pain?

Kiwi investors help local tech firm on path to improving diagnosis prospects

Upstream Medical Technologies has developed technology that could reduce hospital patient admissions of chest pain by up to 40% and is accelerating to offshore trials following a whirlwind capital raise.

See full article from Stuff.co.nz here

‍

Share this post

More Articles

Detecting at-risk heart attack patients, a step closer with $2m investment

Upstream Medical Technologies, a leading deep-tech company focused on developing innovative solutions for heart disease, announced today that it has closed a significant capital round to further advance its frontline diagnostic tests for cardiac diseases.

Upstream commences testing Marker C on the APACE cohort

The next phase of development is now underway, with the commencement of testing Marker C on the APACE cohort.

December 12, 2022

Analysis of Marker C in clinical triage protocols available

By shifting chest pain patients with intermediate troponins to low or high-risk categories, Marker C could rapidly triage 10-35% more chest pain patients in the emergency department.

Connect with us

info@upstreamdx.com

Auckland, New Zealand